Current and future therapeutic approaches for the treatment of small cell lung cancer

Antonio Rossi, Rebecca Tay, Jaseela Chiramel, Arsela Prelaj, Raffaele Califano

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1 year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC. Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC. Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC.

Original languageEnglish
Pages (from-to)473-486
Number of pages14
JournalExpert Review of Anticancer Therapy
Volume18
Issue number5
DOIs
Publication statusPublished - May 4 2018

Fingerprint

Small Cell Lung Carcinoma
Therapeutics
Drug Therapy
Immunotherapy
Recurrence
Pharmaceutical Preparations

Keywords

  • Durvalumab
  • immunotherapy
  • ipilimumab
  • nivolumab
  • pembrolizumab
  • rovalpituzumab tesirine
  • SCLC
  • second-line
  • targeted therapy
  • tremelimumab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Current and future therapeutic approaches for the treatment of small cell lung cancer. / Rossi, Antonio; Tay, Rebecca; Chiramel, Jaseela; Prelaj, Arsela; Califano, Raffaele.

In: Expert Review of Anticancer Therapy, Vol. 18, No. 5, 04.05.2018, p. 473-486.

Research output: Contribution to journalReview article

Rossi, Antonio ; Tay, Rebecca ; Chiramel, Jaseela ; Prelaj, Arsela ; Califano, Raffaele. / Current and future therapeutic approaches for the treatment of small cell lung cancer. In: Expert Review of Anticancer Therapy. 2018 ; Vol. 18, No. 5. pp. 473-486.
@article{b1b095e361784bc5adc01052a13bfdc9,
title = "Current and future therapeutic approaches for the treatment of small cell lung cancer",
abstract = "Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1 year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC. Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC. Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC.",
keywords = "Durvalumab, immunotherapy, ipilimumab, nivolumab, pembrolizumab, rovalpituzumab tesirine, SCLC, second-line, targeted therapy, tremelimumab",
author = "Antonio Rossi and Rebecca Tay and Jaseela Chiramel and Arsela Prelaj and Raffaele Califano",
year = "2018",
month = "5",
day = "4",
doi = "10.1080/14737140.2018.1453361",
language = "English",
volume = "18",
pages = "473--486",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Current and future therapeutic approaches for the treatment of small cell lung cancer

AU - Rossi, Antonio

AU - Tay, Rebecca

AU - Chiramel, Jaseela

AU - Prelaj, Arsela

AU - Califano, Raffaele

PY - 2018/5/4

Y1 - 2018/5/4

N2 - Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1 year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC. Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC. Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC.

AB - Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1 year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC. Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC. Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC.

KW - Durvalumab

KW - immunotherapy

KW - ipilimumab

KW - nivolumab

KW - pembrolizumab

KW - rovalpituzumab tesirine

KW - SCLC

KW - second-line

KW - targeted therapy

KW - tremelimumab

UR - http://www.scopus.com/inward/record.url?scp=85045296183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045296183&partnerID=8YFLogxK

U2 - 10.1080/14737140.2018.1453361

DO - 10.1080/14737140.2018.1453361

M3 - Review article

C2 - 29544351

AN - SCOPUS:85045296183

VL - 18

SP - 473

EP - 486

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 5

ER -